PPARG and Other metabolic disease: Although PPARγ agonists such as rosiglitazone and pioglitasone improve insulin resistance and glucose tolerance in obese mice models, previous studies also have shown that inhibition of PPARγ signaling significantly improve metabolic disorders including obesity, dyslipidemia, and diabetes [20, 22].